您当前所在的位置:首页 > 产品中心 > 产品详细信息
4618-18-2 分子结构
点击图片或这里关闭

(2S,3R,4S,5R,6R)-2-{[(2R,3S,4S,5R)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

ChemBase编号:463
分子式:C12H22O11
平均质量:342.29648
单一同位素质量:342.11621152
SMILES和InChIs

SMILES:
O([C@H]1[C@H](O)[C@@](O[C@@H]1CO)(O)CO)[C@@H]1O[C@@H]([C@H](O)[C@H](O)[C@H]1O)CO
Canonical SMILES:
OC[C@H]1O[C@]([C@H]([C@@H]1O[C@@H]1O[C@H](CO)[C@@H]([C@@H]([C@H]1O)O)O)O)(O)CO
InChI:
InChI=1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12-/m1/s1
InChIKey:
JCQLYHFGKNRPGE-FCVZTGTOSA-N

引用这个纪录

CBID:463 http://www.chembase.cn/molecule-463.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
(2S,3R,4S,5R,6R)-2-{[(2R,3S,4S,5R)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
IUPAC传统名
lactulose
商标名
Acilac
Bifiteral
Cephulac
Cholac
Chronulac
Constilac
Constulose
D-Lactulose
Duphalac
Enulose
Evalose
Fructofuranose
Generlac
Heptalac
Isolactose
Kristalose
Lactulosa [INN-Spanish]
Lactulosa [Spanish]
Lactulose [USAN:BAN:INN:JAN]
Lactulose, ~98%
Lactulosum [INN-Latin]
Lactulosum [Latin]
Laevolac
Lattulosio [Italian]
Laxilose
Portalac
别名
Lactulose
CAS号
4618-18-2
PubChem SID
46506757
160963926
PubChem CID
11333

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID
DrugBank DB00581 external link
PubChem 11333 external link
数据来源 数据ID 价格

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 10.279233  质子受体 11 
质子供体 LogD (pH = 5.5) -4.528842 
LogD (pH = 7.4) -4.5294075  Log P -4.528835 
摩尔折射率 68.7741 cm3 极化性 28.969793 Å3
极化表面积 189.53 Å2 可自由旋转的化学键
里宾斯基五规则 false 
Log P -3.26  LOG S 0.36 
溶解度 7.92e+02 g/l 

分子性质

分子性质

理化性质 生物活性(PubChem)
溶解度
764 mg/mL expand 查看数据来源
疏水性(logP)
-4.3 expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank
DrugBank -  DB00581 external link
Item Information
Drug Groups approved
Description A synthetic disaccharide used in the treatment of constipation and hepatic encephalopathy. It has also been used in the diagnosis of gastrointestinal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p887)
Indication For the treatment of constipation and hepatic encephalopathy.
Pharmacology Therapeutically, lactulose has laxative and ammonia-detoxifying actions. In treating constipation lactulose metabolites draw water into the bowel, causing a cathartic effect through osmotic action.
Toxicity LD50=18.2 g/kg (oral, rat). Side effects include diarrhea and resultant dehydration.
Affected Organisms
Humans and other mammals
Biotransformation Lactulose is completely metabolized in the colon by enteric bacteria, and no lactulose is excreted in the feces.
Absorption Poorly absorbed from the gastrointestinal tract as no human enzyme that is capable of hydrolysis of this disaccharide is present in human gastrointestinal tissue.
Half Life 1.7-2 hours
Elimination The primary route of elimination is fecal. Urinary excretion has been determined to be 3% or less and is essentially complete within 24 hours.
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
    暂无数据
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle